Exploration of real-world outcomes in patients with previously treated HR+/HER2- and triple negative metastatic breast cancer

Curated electronic health records offer valuable insights into real-world outcomes for patients with advanced tumors. We described real-world treatment effectiveness among patients with HR+/HER2- metastatic breast cancer (mBC) and metastatic triple-negative breast cancer (mTNBC) using ConcertAI Patient360™ Breast Cancer dataset. Patients initiating therapies selected based on literature review and data availability in the metastatic setting between January 1, 2016, and November 30, 2021, were included. Real-world response rate (rwRR), progression-free survival (rwPFS), overall survival (rwOS), time-to-next treatment (rwTTNT), and time-to-discontinuation (rwTTD) were assessed. Three HR+/HER2- mBC cohorts included 292 patients treated with palbociclib + fulvestrant, 274 patients treated with fulvestrant monotherapy, and 381 patients treated with paclitaxel-based therapy; the mTNBC cohort included 247 chemotherapy-treated patients. Median rwOS in three HR+/HER2- cohorts ranged from 15.6 to 32.3 months and was 13 months in mTNBC; median rwPFS ranged from 5.6 to 8.6 months, and 4.4 months, respectively. The alignment between several real-world and clinical trial endpoints is encouraging and supports the utility of real-world data in contextualizing outcomes, though interpretation may be influenced by data completeness and variability in clinical documentation. These insights are particularly relevant for populations with persistent unmet clinical needs.